Skip to main content

Democratizing diagnostics

The Nostics platform will bring instant and reliable testing for bacteria and fungi to every corner of the world.

the essential

Diagnostics open the pathway to effective patient care and health management - from treatment to control and prevention of diseases. However, in comparison to medicines and vaccines, diagnostics are often overlooked and the allocated resources low. Particularly in rural or lower-income areas, access to testing is poor and healthcare workers have to rely on empirical and syndromic diagnoses. Frequent misdiagnosis and unnecessary treatments are the result, leading to a high toll in human suffering and healthcare resources.

We want to change that.

Forging the path to effective care

With our novel, hand-held platform, we provide fast, affordable and data-driven diagnostics to close the gap between diagnostic needs and diagnostic access.

For effective treatment and less days of suffering - in every corner of the world.

There was no test that had it all…


…until now

Test anywhere

To help people in even the remote locations on earth.

Fast time-to-result

For correct treatment-decisions within a doctor’s visit.


To use without the need for highly experienced personnel.

(to all)

To make sure that when it’s available, it is really available.

Health for All

“Ensure healthy lives and promote well-being for all at all ages” is the third of the United Nations Sustainable Development goals. With our platform, we hope to address many of the challenges that stand in the way reaching it and providing Health For All. By providing diagnostic access to everyone, everywhere, we want to bring efficiency and clarity to patient care, promote antimicrobial stewardship, and improve disease monitoring. Read more about these challenges below.

“If we don’t act now, by 2050 one person will die every three seconds due to Antimicrobial Resistance.”

Only with quality data from all countries can we respond to the growing threat of AMR.

What is Antimicrobial Resistance?

Antimicrobial resistance (AMR) is defined as the ability of microorganisms (like bacteria, fungi or viruses) to resist the effect of antimicrobial agents such as antibiotics, antifungal or antiviral medicines. Currently, AMR is directly linked to 1.3 million deaths world wide, a number expected to increase to 10 million by 2050.
A lack of effective and quick diagnostic solutions have promoted self-medication or empirical antimicrobial treatments by clinicians and GPs as a prompt and easy solution to infections, ultimately accelerating the rise of AMR.

If AMR is not curbed, it will lead to rising infection rates and harder-to-treat infections that require more expensive treatment or longer hospitalisation times because of ineffective antimicrobials.

Antimicrobial-resistant infections currently claim at least 50,000 lives each year across Europa and the US alone.
By 2050, AMR will result in a 100.2 trillion USD loss in GDP.
In some countries more than 50% of patients with an E.coli infection don’t respond to first line antibiotics.
Between 2000 and 2010 antibiotics consumption rose nearly 40%.
People with MRSA infections are 64% more likely to die than people with drug-sensitive infections.
Gonorrhea has quickly developed resistance to all but one class of antibiotics.

To truly understand the extent of the global threat and mount an effective public health response to AMR, we must scale up microbiology testing and provide quality-assured data across all countries, not just wealthier ones.

Dr Tedros Adhanom GhebreyesusWHO Director-General
Close Menu

Nostics B.V.
Pietersbergweg 199
1105 BV Amsterdam
The Netherlands

Nostics Inc. USA
1 Broadway,
Cambridge, MA,
02142 United States


T: +31(0)85 073 7100